Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026

$3,850.00$5,850.00

Published on: April 1, 2021
Clear
SKU: GMS-1226 Category:

OVERVIEW

The Autoinjectors Market is expected to reach USD 5576.69 million by 2026, growing at a CAGR of 18.1% during the forecast period. The market is growing at a significant rate due to mounting occurrence of chronic and lifestyle associated diseases, escalating occurrence of anaphylaxis, and advancement in technology. The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits.

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026 1

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026 2

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026 3

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026 4

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026 5

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026 6

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026 7

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – 2021 to 2026 8

TABLE OF CONTENT

1 Global Autoinjectors Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Autoinjectors Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Autoinjectors Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Autoinjectors Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Autoinjectors Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Autoinjectors Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Autoinjectors Market – By Type (Market Size – & million/billion)
8.1 Disposable Autoinjectors
8.2 Reusable Autoinjectors

9 Global Autoinjectors Market – By Therapy
9.1 Rheumatoid Arthritis
9.2 Multiple Sclerosis
9.3 Diabetes
9.4 Anaphylaxis
9.5 Other

10 Global Autoinjectors Market – By End-User
10.1 Home Care Settings
10.2 Hospital & Clinics

11 Global Autoinjectors Market – By Geography (Market Size – & million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa

12 Global Autoinjectors Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships

13 Global Autoinjectors Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Abbvie
13.3 Mylan
13.4 ELI Lilly
13.5 Ypsomed
13.6 Haselmeier
13.7 Shl Group (Scandinavian Health Limited)
13.8 Amgen
13.9 Becton, Dickinson and Company
13.10 Owen Mumford
13.11 Consort Medical
13.12 Company 11 & more

14 Global Autoinjectors Market – Appendix
14.1 Sources
14.2 Abbreviations